Business Description
Gufic Biosciences Ltd
ISIN : INE742B01025
Share Class Description:
BOM:509079: Shs DematerialisedCompare
Compare
Traded in other countries / regions
509079.India IPO Date
2000-09-25Description
Gufic Biosciences Ltd is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Geographically, it derives a majority of revenue from India. Its product portfolio includes Criticare; Criticare Life; Ferticare; Spark; Herbal and other products. The company's lyophilized product includes antibiotics, anti-fungal, cardiac, infertility, anti-viral and a proton-pump inhibitor. It derives maximum revenue from India.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.07 | |||||
| Equity-to-Asset | 0.52 | |||||
| Debt-to-Equity | 0.52 | |||||
| Debt-to-EBITDA | 2.01 | |||||
| Interest Coverage | 8.23 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 6.61 | |||||
| Beneish M-Score | -1.71 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 15.8 | |||||
| 3-Year EBITDA Growth Rate | 19.1 | |||||
| 3-Year EPS without NRI Growth Rate | 25.1 | |||||
| 3-Year Book Growth Rate | 43.7 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 50.27 | |||||
| 9-Day RSI | 55.62 | |||||
| 14-Day RSI | 56.53 | |||||
| 6-1 Month Momentum % | 21.27 | |||||
| 12-1 Month Momentum % | 26.27 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.63 | |||||
| Quick Ratio | 1.11 | |||||
| Cash Ratio | 0.05 | |||||
| Days Inventory | 183.52 | |||||
| Days Sales Outstanding | 143.73 | |||||
| Days Payable | 154.41 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.02 | |||||
| Dividend Payout Ratio | 0.01 | |||||
| 3-Year Dividend Growth Rate | 26 | |||||
| Forward Dividend Yield % | 0.02 | |||||
| 5-Year Yield-on-Cost % | 0.05 | |||||
| 3-Year Average Share Buyback Ratio | -1.1 | |||||
| Shareholder Yield % | 0.71 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 49.89 | |||||
| Operating Margin % | 16.99 | |||||
| Net Margin % | 11.08 | |||||
| FCF Margin % | -15.67 | |||||
| ROE % | 17.01 | |||||
| ROA % | 8.05 | |||||
| ROIC % | 11.19 | |||||
| 3-Year ROIIC % | 7.06 | |||||
| ROC (Joel Greenblatt) % | 15.97 | |||||
| ROCE % | 18.89 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 55.04 | |||||
| PE Ratio without NRI | 53.96 | |||||
| Shiller PE Ratio | 85.84 | |||||
| PEG Ratio | 2.3 | |||||
| PS Ratio | 6.09 | |||||
| PB Ratio | 8.14 | |||||
| Price-to-Tangible-Book | 8.23 | |||||
| EV-to-EBIT | 38.13 | |||||
| EV-to-EBITDA | 33.69 | |||||
| EV-to-Revenue | 6.46 | |||||
| EV-to-FCF | -41.21 | |||||
| Price-to-DCF (Earnings Based) | 2.07 | |||||
| Price-to-Median-PS-Value | 2.47 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.72 | |||||
| Price-to-Graham-Number | 4.44 | |||||
| Price-to-Net-Current-Asset-Value | 97.53 | |||||
| Earnings Yield (Greenblatt) % | 2.62 | |||||
| FCF Yield % | -2.57 | |||||
| Forward Rate of Return (Yacktman) % | 19.11 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Gufic Biosciences Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 7,667.538 | ||
| EPS (TTM) (₹) | 8.47 | ||
| Beta | 0.32 | ||
| Volatility % | 35.04 | ||
| 14-Day RSI | 56.53 | ||
| 14-Day ATR (₹) | 20.880199 | ||
| 20-Day SMA (₹) | 453.0925 | ||
| 12-1 Month Momentum % | 26.27 | ||
| 52-Week Range (₹) | 278 - 501.1 | ||
| Shares Outstanding (Mil) | 100.28 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Gufic Biosciences Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Gufic Biosciences Ltd Stock Events
| Event | Date | Price(₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Gufic Biosciences Ltd Frequently Asked Questions
What is Gufic Biosciences Ltd(BOM:509079)'s stock price today?
The current price of BOM:509079 is ₹466.20. The 52 week high of BOM:509079 is ₹501.10 and 52 week low is ₹278.00.
When is next earnings date of Gufic Biosciences Ltd(BOM:509079)?
The next earnings date of Gufic Biosciences Ltd(BOM:509079) is 2025-02-14 Est..
Does Gufic Biosciences Ltd(BOM:509079) pay dividends? If so, how much?
The Dividend Yield %  of Gufic Biosciences Ltd(BOM:509079) is 0.02% (As of Today), Highest Dividend Payout Ratio of Gufic Biosciences Ltd(BOM:509079) was 0.09. The lowest was 0.01. And the median was 0.02. The  Forward Dividend Yield % of Gufic Biosciences Ltd(BOM:509079) is 0.02%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers